“ Idiopathic anaphylaxis successfully treated with omalizumab”
Idiopathic anaphylaxis (IA) is a rare condition that can be lethal.1Prophylactic regimens for frequent attacks are not yet standardized. These may include long-term systemic corticosteroids, high dose antihistamines, and mast cell stabilizers. Despite these regimens, patients may become corticosteroid dependent (20%) and develop potential side effects 2. Omalizumab is a monoclonal anti-IgE antibody which is indicated in uncontrolled moderate to severe persistent asthma3 and chronic idiopathic urticaria4.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Maria C. Sanchez-Valenzuela, Juan C. Garcia-Saucedo, Gabriel Motoa, Ismael Carrilo-Martin, Alexei Gonzalez-Estrada Tags: Letters Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Asthma | Corticosteroid Therapy | Xolair